Clinical Trial: Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label Method

Brief Summary: The safety and efficacy of L059 will be evaluated in patients who completed "N165 Clinical Trial of L059". They will receive L059 at a daily dose from 1,000 mg to 3,000 mg in addition to their standard concomitant AEDs

Detailed Summary:
Sponsor: UCB Pharma

Current Primary Outcome: Frequency of AE/ADR

Original Primary Outcome: Same as current

Current Secondary Outcome: Seizures frequency per week

Original Secondary Outcome: Same as current

Information By: UCB Pharma

Dates:
Date Received: September 8, 2005
Date Started: September 2001
Date Completion:
Last Updated: March 3, 2015
Last Verified: September 2009